BioStem Technologies gains four U.S. design patents for placental allograft technology
Seeking Alpha ·
BioStem Technologies ( BSEM ) said on Wednesday the U.S. Patent and Trademark Office issued four U.S. design patents covering its proprietary fenestrated human placental allograft technologies. The patents cover allograft designs for surgical and wound care applications, including features intended to support fluid management, drainage, flexibility, and tissue integration. The company said the additions expand its intellectual property portfolio, which now includes more than 100 patents and patent applications worldwide. BioStem Technologies, Inc. (BSEM) Q1 2026 Earnings Call Transcript BioStem Technologies prices $2.5M private placement Seeking Alpha’s Quant Rating on BioStem Technologies Historical earnings data for BioStem Technologies Financial information for BioStem Technologies
DYAX Investor Sentiment
Bullish (Long) 62% · Bearish (Short) 38%
449 participants
Related News
- Are small caps showing signs of investor fatigue? – analyst
- Rapidus plans to establish its 2nm foundry process at or less than TSMC's pricing
- Wholesale inventories growth was revised down to 0.1% in May
- Wall Street slides lower as U.S.-Iran tensions flare back up
- IMF sees 3.0% global growth in 2026, 3.4% in 2027
- Trump warns of imminent new strikes on Iran - report